CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Olsen, S. C.
Right arrow Articles by Waters, W. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Olsen, S. C.
Right arrow Articles by Waters, W. R.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, October 2006, p. 1098-1103, Vol. 13, No. 10
1071-412X/06/$08.00+0     doi:10.1128/CVI.00213-06

Immune Responses of Elk to Initial and Booster Vaccinations with Brucella abortus Strain RB51 or 19

S. C. Olsen,1* S. J. Fach,2 M. V. Palmer,1 R. E. Sacco,2 W. C. Stoffregen,1 and W. R. Waters1

Bacterial Diseases of Livestock,1 Respiratory Diseases of Livestock Research Units, National Animal Disease Center, Agricultural Research Service, U.S. Department of Agriculture, Ames, Iowa 500102

Received 7 June 2006/ Returned for modification 14 July 2006/ Accepted 28 July 2006

Previous studies have suggested that currently available brucellosis vaccines induce poor or no protection in elk (Cervus elaphus nelsoni). In this study, we characterized the immunologic responses of elk after initial or booster vaccination with Brucella abortus strains RB51 (SRB51) and 19 (S19). Elk were vaccinated with saline or 1010 CFU of SRB51 or S19 (n = seven animals/treatment) and booster vaccinated with a similar dosage of the autologous vaccine at 65 weeks. Compared to nonvaccinates, elk vaccinated with SRB51 or S19 had greater (P < 0.05) antibody responses to SRB51 or S19 after initial vaccination and after booster vaccination. Compared to nonvaccinated elk, greater (P < 0.05) proliferative responses to autologous antigen after initial vaccination occurred at only a few sample times in SRB51 (6, 14, and 22 weeks) and S19 (22 weeks) treatment groups. In general, proliferative responses of vaccinates to nonautologous antigens did not differ (P > 0.05) from the responses of nonvaccinated elk. Gamma interferon production in response to autologous or nonautologous Brucella antigens did not differ (P > 0.05) between controls and vaccinates after booster vaccination. Flow cytometric techniques suggested that proliferation occurred more frequently in immunoglobulin M-positive cells, with differences between vaccination and control treatments in CD4+ and CD8+ subset proliferation detected only at 22 weeks after initial vaccination. After booster vaccination, one technique ([3H]thymidine incorporation) suggested that proliferative responses to SRB51 antigen, but not S19 antigen, were greater (P < 0.05) in vaccinates compared to the responses of nonvaccinates. However, in general, flow cytometric and other techniques failed to detect significant anamnestic responses to autologous or nonautologous Brucella antigens in S19 or SRB51 vaccinates after booster vaccination. Although some cellular immune responses were detected after initial or booster vaccination of elk with SRB51 or S19, our data suggest that responses tend to be transient and much less robust than previously reported in SRB51-vaccinated cattle (Bos taurus) or bison (Bison bison). These data may explain why the vaccination of elk with S19 and SRB51 induces poor protection against brucellosis.


* Corresponding author. Mailing address: NADC, USDA, ARS, 2300 Dayton Ave., Ames, IA 50010. Phone: (515) 663-7230. Fax: (515) 663-7458. E-mail: Solsen{at}nadc.ars.usda.gov.


Clinical and Vaccine Immunology, October 2006, p. 1098-1103, Vol. 13, No. 10
1071-412X/06/$08.00+0     doi:10.1128/CVI.00213-06







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2006 by the American Society for Microbiology. All rights reserved.